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Introduction 
Transglutaminases (TGs) are a protein family consisting 
of 9 members in mammals: factor XIII, protein band 4.2, 
and transglutaminases 1 to 7.
1-3 
They belong to a papain-
like superfamily.
1,4
 One of the most attractive members 
of this family is transglutaminase 2. 
Transglutaminase 2 (TG2) also known as tissue 
transglutaminase (tTG) is a monomeric protein with 76-
80 kDa molecular mass which ubiquitously is expressed 
in many tissues. The enzyme has been found in the 
cytosol and other cellular compartments such as 
mitochondria,
5
 and extracellular matrix. TG2, as a 
multifunctional protein, has a number of calcium 
dependent enzymatic activities such as 
transamidation/crosslinking
6,7
 (Table 1). TG2 interacts 
non-covalently with several cellular and extracellular 
matrix (ECM) proteins such as fibronectin,
4
 integrin,
6
 
and heparan sulfates.
8
 The enzyme has been involved 
(calcium independently) in multiple cellular processes 
for instance cellular proliferation and signal 
transduction.
5,9
 TG2 has also been implicated in some of 
diseases such as celiac disease,
10
 certain types of cancer,
7
 
and several neurodegenerative diseases including 
Alzheimer’s disease (AD) (Table 1).11,12 TG2 has been 
found as a novel pharmacological target in 
neurodegenerative diseases.
13
 Despite of extensive 
studies that have been done on different aspects of TG2 
specially in physiopathology of diseases,
2,7,14 
its 
functions, activation, and novel inhibitors for the enzyme 
has not been completely worked out. For this reason, we 
have aimed at the subcloning and expression of TG2 
enzyme in this study. 
Proteins produced in the baculovirus system are very 
similar to human proteins in terms of post-translational 
modifications (e.g., N- and O-glycosylation, 
phosphorylation) and biological activity. Moreover, the 
baculovirus expression vector system (BEVS) is the 
preferred expression system for production of large 
recombinant proteins.
15
 Bac-to-Bac technique is an 
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Abstract 
Purpose: Tissue transglutaminase (TG2) is a unique multifunctional enzyme. The enzyme 
possesses enzymatic activities such as transamidation/crosslinking and non-enzymatic 
functions such as cell migration and signal transduction. TG2 has been shown to be 
involved in molecular mechanisms of cancers and several neurodegenerative diseases such 
as Alzheimer’s disease. The present study aimed at cloning and expression of full length 
human TG2 in Bac-to-Bac baculovirus expression system and evaluation of its activity. 
Methods: pFastBac HTA donor vector containing coding sequence of human TG2 was 
constructed. The construct was transformed to DH10Bac for generating recombinant 
bacmid. The verified bacmid was transfected to insect cell line (Sf9). Expression of 
recombinant TG2 was examined by RT-PCR, SDS-PAGE and western blot analysis. 
Functional analysis was evaluated by fluorometric assay and gel electrophoresis.  
Results: Recombinant bacmid was verified by amplification of a band near to 4500 bp. 
Expression analysis showed that the enzyme was expressed as a protein with a molecular 
weight near 80 kDa. Western blot confirmed the presence of TG2 and the activity assays 
including flurometric assay indicated that the recombinant TG2 was functional. The 
electrophoresis assay conformed that the expressed TG2 was the indeed capable of 
crosslinking in the presence of physiological concentration calcium ions. 
Conclusion: Human TG2 was expressed efficiently in the active biological form in the Bac-
to-Bac baculovirus expression system. The expressed enzyme could be used for medical 
diagnostic, or studies which aim at finding novel inhibitors of the enzymes . To best of our 
knowledge, this is probably the first report of expression of full length human tissue 
transglutaminase (TG2) using the Bac-to-Bac expression system. 
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efficient and widely used method in BEVS.
16
 In the 
present study, the expression of full length recombinant 
human tissue transglutaminase (TG2) is reported in the 
Bac-to-Bac baculovirus expression system, for the first 
time, and its activity has been also evaluated. 
 
Table 1. Summary of TG2 characteristics and properties 
Protein name 
Gene/Map 
locus 
Residues/Molecular 
Mass (kDa) 
Structure 
Tissue 
localization 
Chemical 
reaction 
Physiological 
functions 
Related disease 
Transglutaminase 
2 [TG2, tissue TG, 
TGc, tTG] 
TGM2/ 
20q11-12 
686-687/ 74-80 
4 domain: 
β-
sandwich 
catalytic 
core 
β-barrel 1 
β-barrel 2 
Cytosolic, 
nucleus, 
mitochondria, 
cell 
membrane 
Transamidation/ 
crosslinking, 
deaminase 
GTPase, ATPase 
isomerase 
Cell adhesion, 
migration, 
growth, 
proliferation, 
differentiation, 
cell signaling, 
Coeliac disease, 
neurodegenerative 
disease [Alzheimer, 
Huntington,  
Parkinson]  cancer,  
metastasis 
 
Materials and Methods 
Reagents, cells and Antibodies 
All restriction enzymes, X-gal, and IPTG were obtained 
from Fermentas (Lithuania). dNTP and Taq DNA 
polymerase were purchased from Roche (Germany). 
Culture mediums were purchased from Gibco (USA). 
Cellfectin II and TRIZOL were purchased from 
Invitrogen (USA). Coomassie brilliant blue, HCL, NaOH 
and boric acid were from Merck (Germany). 
Nitrocellulose membrane from Schleicher & Schuell 
BioScience (Germany). Gentamicin, Tetracycline, 
Kanamycin, Tris, SDS, Protease inhibitor, Laemmli 
buffer, DAB, dansylcadaverine, N,N dimethyl casein, 
EDTA, Cacl2 and DTT were obtained from Sigma 
(USA). Primers were synthesized by Pishgam biotech 
(Iran). cDNA synthesis were performed by Takara kit 
(Japan). Spodoptera frugiperda (Sf9) cells were from 
National Cell Bank of Iran (NCBI, Pasteur Institute of 
Iran). Recombinant human transglutaminase 2/TGM2 
was purchased from R&D systems (USA). Anti-TG2 
antibody was from Abcam (UK) and anti-rabbit IgG was 
obtained from Santa Cruz Biotechnology (USA). 
 
Plasmid Construction of the recombinant tissue 
transglutaminase (TG2) 
Human TG2 cDNA was obtained from our previous 
study.
17
 The TG2 cDNA that was cloned using EcoRI, 
and XhoI into pET-28, was digested with the same 
restriction enzymes and the cleaved insert containing the 
entire TG2 cDNA was purified from the gel and 
subcloned into pUC57. After confirming correct clones, 
the TG2/pUC57 plasmid digested with EcoRI and 
HindIII and the insert subcloned into pFastBacHTA 
vector. This vector adds a hexa-histidine tag (His-tag) to 
the N-terminal of the expressed protein. 
Double digestion using EcoRI, and HindIII restriction 
enzymes and gene sequencing were used for 
confirmation the correct TG2 subcloning and coding 
sequence. The integrity of final construct was also 
confirmed again by PCR using specific primers 
5'CCGGAATTCATGGCCGAGGAGCTGGTCTTAGA
GAGG3' (TG2-forward) and 
5'AACCTCGAGTTAGGCGGGGCCAATGATGACAT
TCC3' (TG2-reverse).
17
 For PCR, the reaction mixture 
(25 μL) was composed of 15 ng extracted plasmid, 1× 
PCR buffer, 200 μM each dNTP, 1.5 unit of Taq DNA 
polymerase and 0.6 μM each primers. The PCR was 
performed by 35 cycles of 94 °C for 30 s, 57 °C for 40 s 
and extension at 72 °C for 2.5 min. 
 
Generation of recombinant baculoviruse 
The donor plasmid (pFastBac HTA) containing the TG2 
coding sequence transformed into DH10 bacteria. The 
DH10 bacteria contain the baculovirus genome as a 
bacmid DNA and helper plasmid. As a result of 
homologous recombination, recombinant bacmid was 
produced.
18,19
 
The transformed DH10Bac bacteria were grown for 48-
72 h at 37 °C and isolated white colonies on selective LB 
agar plates containing 7 µg/ml gentamicin, 10 µg/ml 
tetracycline, 50 µg/ml kanamycin, 100 µg/ml X-gal, and 
40 µg/ml IPTG. To ensure the verification of correct 
homologous recombination, gene amplification method 
using pUC/M13 forward and reverse primers was 
performed. The verified recombinant bacmid was used 
for baculovirus production.
18
 
Spodoptera frugiperda (Sf9) insect cells that were 
adapted to serum-free medium, incubated at 27 °C 
without CO2 and the cells were grown in SF-900 II SFM 
medium lacking in antibiotics and antimycotics reagents. 
Transfection was performed by using the cells, 2μg 
verified recombinant bacmid DNA from previous step, 
and 10μl Cellfectin II reagent in 1 mL SF-900 II SFM 
without antibiotics following manufacturer's instruction 
as reported in previous study.
18
 After incubating at 27 °C 
for 5 h, the transfection mixture was changed with 2.5 ml 
serum-free medium. Transfected cells were allowed to 
grow in monolayer culture and were observed daily for 
signs of viral infection and cytopathic effects. 
 
Expression of recombinant transglutaminase 
For protein expression, Sf9 cells (10
6
 cells) were 
transfected with recombinant baculovirus. Preliminary 
assessment showed that protein expression was optimal 
when cells were incubated for 96 h at a multiplicity of 
infection (MOI) of 5. After infection, cells were washed 
by cold PBS and lysed with cell lysate buffer (62.5 mM 
Tris-HCl, pH 6.8, 2% SDS) supplemented with protease 
inhibitor cocktail. An equal volume of Laemmli buffer 
(2X) was added to the sample, then samples were heated 
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at 100 °C for 5 min and then the samples were cooled. 
Separation of proteins was done by SDS-PAGE (10%) 
for 90 min at 120 V. Then, proteins were stained with 
Coomassie brilliant blue R-250. 
 
RT-PCR  
Total cellular RNA was prepared from 96 h post 
transfection and untrasfected Sf9 cells (10
6
 cells) by 
TRIZOL reagent.
20
 cDNA synthesis was performed with 
oligo (dT) and random hexamers primers according to 
the protocol provided by the Takara manufacturer. The 
synthesized cDNAs were amplified by PCR using 
specific primers (TG2-forward and TG2-reverse). 
 
Western blotting of TG2 recombinant 
Following SDS–PAGE, the isolated proteins were 
transferred onto nitrocellulose membrane using a Bio-
Rad wet blot system for 100 min at 100 V. The 
membranes were blocked with 2% BSA in PBS for 
overnight. After gently washing, the membranes were 
incubated with rabbit anti-TG2 antibody (1/2000, 
Abcam) for 1.5 h at RT. The detector layer was anti-
rabbit IgG (1:10000, Santa Cruz Biotechnology). Finally, 
visualization was performed with DAB (Sigma).
21,22
 
 
Activity assay 
The determination of TG2 activity was based on the 
incorporation of dansylcadaverin (CAD) (Sigma) as acyl 
acceptor (amine donor) into N,N dimethyl casein 
(Sigma) as acyl donor (amine acceptor) by fluorometric 
assay. Assay buffer containing 100 mM Tris (pH 8), 10 
mM CaCl2, 0.2 mg/ml N,N dimethyl casein, 0.5 mM 
dansycadaverin and 10 mM DTT. EDTA (100 mM) was 
added to chelate Ca
2+
 ions. Recombinant human 
transglutaminase 2/TGM2 (1 μg) used for comparison of 
activities and as a positive control. Semipurified 
supernatant of 96 h post transfected and untransfected 
cell lysate were concentrated, and were added at 500 µg 
concentration. The reaction mixtures were incubated for 
0, 30, 60, 120, and 180 min at 37 °C. The relative 
fluorescence of the reaction mixtures were measured in 
triplicate to achieve standard deviation using Bio-tek 
instrument (Synergy 4) at λexc 280 nm, λem 538 nm.
23
 
To ensure that we detect TG2 activity, we performed the 
fluorometric with much longer incubation time for 16 h 
at 37 °C exactly as the aforementioned procedure except 
changing the EDTA concentration to 25 mM. After 16 h 
incubation, the reactions were stopped by adding 0.4M 
HCL and the samples were centrifuged to collect protein 
aggregates at 10000 rpm for 10 min. The pellets were 
washed by ethanol/acetone (1:1, v/v). Pellets air–dried 
and finally they were dissolved in 0.1M NaOH and 0.7M 
boric acid. The relative fluorescent of samples were 
measured at λexc 488 nm and λem 521 nm.
24
  
For better confirming fluorescence activity assay, the 
reaction mixtures that were incubated at 180 min and 16 
h in fluorometric assay, were subjected to SDS-PAGE 
(15%) at 100 V for 120 min (after adding Laemmli 
buffer and boiling for 5 min). The gels were 
photographed under UV light as previously 
performed.
24,25
 The gel was also stained by Coomassie 
brilliant blue R-250. 
 
Results 
Donor vector construction with a predesigned cassette 
(recombinant pFastBac HTA-TG2) 
The digestion profile of plasmid pFastBac HTA using 
restriction enzyme BglI resulted in three fragments of 
2508, 1268, 1080 base pairs, verified the donor vector 
(Figure 1A). For subcloning TG2 coding sequence
17
 into 
pFastBac HTA donor vector (pFastBac HTA-TG2), 
recombinant cloning vector containing TG2 was digested 
by EcoRI and Hind III restriction enzymes (Figure 1B). 
After ligation and selection of correct constructs, DNA 
sequencing of recombinant pFastBacHTA-TG2 
confirmed the existence of coding sequence in the 
correct frame of the vector, without any mutation or 
alteration in TG2 sequences. 
 
 
Figure 1. Verification of empty pFastBac HTA donor vector and 
TG2 subcloned (pFastBac HTA-TG2) by restriction enzymes. (A) 
Empty plasmid pFastBac HTA were cut with Bgl I. 1,1Kb DNA 
ladder; 2,undigested pFastBac HTA and 3,digested pFastBac 
HTA. (B) pFastBac HTA-TG2 digested with EcoR I and Hind III. 
1,undigested pFastBac HTA-TG2, 2,digested pFastBac HTA-
TG2 and 3,1Kb DNA ladder. 
 
Analyzing Recombinant Bacmid DNA by PCR 
PCR analysis was used to verify the presence of TG2 
(gene of interest) in the recombinant bacmid using 
pUC/M13 forward and reverse primers. A PCR product 
near 4500 bp on the agarose gel verified the presence of 
TG2 coding sequence and correct homologous 
recombination in the bacmid (Figure 2). 
 
Expression analysis of the TG2 by RT-PCR, SDS-
PAGE and Western blot 
Contamination of the SF9 cell line with mycoplasma was 
investigated using universal specific primer.
26
 Moreover, 
cross-contamination and misidentification of this cell 
line were investigated using PCR and 13 human short 
tandem repeat (STR) primers (data not shown).
27
 After 
transfection of the bacmid, as explained in Materials and 
Methods, the expression of TG2 was detected at the 
transcriptional level. RT-PCR was used for mRNA 
expression after 96 h post infection using specific 
primers (TG2-forward and TG2-reverse). The results 
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revealed that transcription of TG2 as a band near 2082 
bp in the electrophoresis analysis (Figure 3). 
Expression of TG2 was also confirmed by SDS–PAGE 
and Western blot analysis after 96 h post infection. 
Figure 4-A shows the presence of a band measuring 
approximately 80 kDa in the infected cell with 
recombinant baculovirus, confirming the recombinant 
human TG2 presence. To further confirm TG2 
expression, western blot analysis was performed. The 
same band reacted with the anti-human TG2, indicating 
that this band represents the recombinant human TG2 
protein (Figure 4-B). 
 
 
Figure 2. Transposition of TG2 into the bacmid supplied by 
DH10Bac was confirmed using pUC/M13 primers. 1,confirmed 
correct homologous recombination, 2,unrecombinant bacmid of 
DH10Bac as control negative and 3,1Kb DNA ladder. 
 
Activity assay of recombinant TG2 
The transamidation activity of TG2 was determined 
with high sensitivity by continuously following the 
relative rate of fluorescence. The increase in 
fluorescence resulting from covalent attachment of 
dansylcadaverine to N,N dimethyl casein was then 
determined.
24
 Dansylcadaverine has high affinity for 
TG enzymes; its incorporation into N,N dimethyl 
casein relates to an escalation in the quantum yield of 
dansyl group emission.
28
 
 
Figure 3. Detection of expressed TG2 at transcriptional level by 
RT-PCR. 1,no expression in untransfected Sf9 cells (control 
negative), 2,TG2 mRNA expression in 96 h post transfected Sf9 
cells and 3,1Kb DNA ladder. 
 
 
Figure 4. SDS-PAGE and Western blot of equivalent gel. (A) 
Coomassie brilliant blue-stained. (B) Western blot using 
monoclonal TG2 antibody. 1,total cell lysate of untransfected Sf9 
as control negative; 2,total cell lysate of 96h post transfection 
Sf9 cells, and 3, protein molecular weight marker. 
 
After a time course (0-180 min) an increase in 
fluorescence can be observed. The fluorescence values in 
the transfected Sf9 cell lysate ( rec TG2) without EDTA in 
comparison with the corresponding controls, transfected 
Sf9 cell lysate (rec TG2) plus EDTA and untransfected 
Sf9 cell lysate (negative control) without EDTA, were 
greater than 2.5 to 5 folds, respectively (Figure 5). By 
adding EDTA (100 mM), the fluorescence intensity was 
 |    53 
TG2 expression in Bac-to-Bac baculovirus system
Advanced Pharmaceutical Bulletin, 2016, 6(1), 49-56 
greatly diminished, indicating that TG2 activity was 
inhibited by EDTA. Our data showed activity (~2 folds) in 
untransfeceted (Cont Neg) Sf9 cell without EDTA which 
could be probably due to the existence of endogenous 
transglutaminse of Sf9 insect cells
29
 (Figure 5).  
 
 
Figure 5. The activity of the recombinant TG2 was determined 
by fluorometric assay and measured in triplicate at Ex: 280 nm/ 
Em: 538nm. (■) transfected Sf9 cell lysate (rec TG2), (●) 
transfected Sf9 cell lysate (rec TG2) with 100 mM EDTA, (▲) 
untransfected (Cont Neg.) Sf9 cell lysat, (▼) untransfected (Cont 
Neg) Sf9 cell lysat with 100 mM EDTA, (♦) TGM2 (1 μg) with 100 
mM EDTA, (◄) assay buffer without casein, (►) assay buffer 
without dansylcadaverine, ()TGM2 (1 μg) as positive control 
and () assay buffer as Blank. 
 
In order to directly follow the activity of TG2, the 
activity was coupled with gel electrophoresis. Using this 
approach, the product of the enzyme can be directly 
detected by the gel analysis since the UV sensitive 
dansylcadaverine would be added to the substrate by the 
action of the enzyme.  When the fluorescence assay was 
examined on the SDS-PAGE, the detection of UV 
sensitive substrate confirmed the actual cross linking 
reaction by the recombinant enzyme (Figure 6-A). After 
electrophoresis, the fluorescent band which migrated 
near 30 kDa, represented modified N,N dimethylcasein, 
linked covalently to densylcadaverine (Figure 6-B). The 
fluorescent band of the dansylcadaverine alone (335.46 
Da) is depicted at the lower edge of the gel (Figure 6-A), 
exhibiting relatively high background fluorescence. The 
intensity of rec TG2 and control positive fluorescent 
bands were greatly reduced when EDTA was present in 
the reaction. 
The fluorescence activity assay was also carried out in 
triplicate for 16 h at 37 °C. After 16 h, the reaction 
mixtures were precipitated for measuring its activity. The 
relatives fluorescence of  transfected Sf9 cell lysate (rec 
TG2) in comparison with the corresponding controls, 
transfected Sf9 cell lysate (rec TG2) plus EDTA and 
untransfected (Control negative) Sf9 cell lysate without 
EDTA, were 250 and 5 folds, respectively (Figure 7). 
The huge difference between the incubation time 
indicates that the maximum activity for the enzyme is 
achieved in hours rather than in minutes. We also 
coupled the activity assay (after 16 h) with gel 
electrophoresis as shown in Figure 8. These results 
clearly confirmed the activity of the expressed 
recombinant TG2 in the presence of 10 mM Ca2+ as 
described previously.
17, 23, 24 
 
Figure 6. Fluorescence activity assay confirmed by SDS-PAGE (15%) incubation 180 min. A) Gel was photographed under UV light. B) 
the same gel stained by Coomassie brilliant blue. 1, transfected Sf9 cell lysate (rec TG2), 2, transfected Sf9 cell lysate (rec TG2) with 100 
mM EDTA, 3, untransfected (Cont Neg) Sf9 cell lysate, 4, untransfected (Cont Neg) Sf9 cell lysate with 100 mM EDTA, 5, assay buffer 
without dansylcadaverine, 6, assay buffer without N,N dimethyl casein, 7, TGM2 with 100 mM EDTA, 8, TGM2 as positive control, 9, 
assay buffer as Blank and, 10, protein molecular weight marker. 
 
Discussion 
Tissue transglutaminase is the most abundantly expressed 
intracellular and extracellular enzyme of the 
transglutaminase family that catalyzes the Ca
2+
-dependent 
post-translational modification of proteins. TG2 is a 
unique and multifunctional enzyme, and because of its 
extensive interactions with numerous other gene products, 
the enzyme has a broad substrate specificity. Additionally, 
TG2 has shown non enzymatic (Ca
2+
-independent) 
activities which include cell growth,
11
 adhesion and 
differentiation,
30
 wound healing,
31
 and apoptosis.
5
 
Multiple lines of evidence suggest an involvement of TG2 
in disease pathology such as autoimmune diseases (celiac 
disease), cancer, and neurodegenerative diseases
12
 (Table 
1). TG2 might be an attractive novel pharmacological 
target for treatment of neurodegenerative diseases in 
preventing toxic protein aggregation.
13
 
Although many studies about the diverse aspects of tissue 
transglutaminase (TG2) specially its roles in pathobiology 
of diseases have been reported,
2,7,14
 there have not been 
much reports on the enzyme inhibitors. For this reason the 
expression of recombinant human TG2 enzyme as well as 
the assessment of its in vitro biological activity has been 
undertaken in the present study. 
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Figure 7. The activity of the recombinant TG2 was determined by 
fluorometric assay after 16 h. The relative fluorescence was 
measured in triplicate at Ex: 488 nm/ Em: 521nm. Columns from left 
to right: transfected Sf9 cell lysate (rec TG2), transfected Sf9 cell 
lysate (rec TG2) with 25 mM EDTA, untransfected (Cont Neg) Sf9 
cell lysate, untransfected (Cont Neg) Sf9 cell lysate with 25 mM 
EDTA, assay buffer without casein, assay buffer without 
dansylcadaverine, TGM2 (1 μg) as positive control, TGM2 (1 μg) 
with 25 mM EDTA and assay buffer as Blank 
 
Expressions of human TG2 have already been reported 
in the bacterial expression systems. Shi et al expressed it 
in BL21(DE3) using the pET-30 Ek/LIC vector.
23
 Other 
investigators have also used E. coli expression 
system.
17,32
 Expressions in the aforementioned system 
have led to insoluble inclusion bodies leading to the lack 
of activity for the enzyme. There have been some 
attempts to decrease the TG2 formation of inclusion 
bodies and increase the yield of soluble active 
enzyme.
17,23
 Because the bacterial expression systems do 
not carry out post-translational modifications and lack 
special organelles as compared to mammalian systems, 
this discrepancy could be the main reason for obtaining  
nonfunctional human recombinant proteins such as TG2 
recombinant proteins. Moreover, contamination of 
recombinant protein with endotoxin which is often seen 
with the microbial expression system restrict their 
applications for in vivo studies.
33
  
One of the most common eukaryotic expression systems 
is the baculovirus expression vector system (BEVS). 
BEVS has high levels of heterologous gene expression 
compared to the other eukaryotic expression systems, 
particularly for intracellular proteins. Baculoviruses have 
a restricted host range which are limited to specific 
invertebrate species; therefore, these viruses are safer to 
work in comparison with most mammalian viruses. This 
expression system has also a number of potential benefits 
including correct folding and post-translational 
modification of the recombinant proteins.
16,33-35
 Among 
the various methods of BEVS, Bac-to-Bac technique is a 
rapid, efficient and widely used method.
16
 Our previous 
data showed Bac-to-Bac is more efficient for large scale 
production and has been widely used for mammalian 
recombinant proteins.
18,19
 Osman et al produced 
recombinant human tissue transglutaminase carried a C-
terminal His tag in TriEx baculovirus expression system 
and did not assay its activity.
36
 For identifying the 
recombinants in TriEx baculovirus expression system 
(Novagen), plaque screening and often additional rounds 
are needed to guarantee that the recombinant viral 
preparation are not contaminated with wild-type virus. 
By using site specific transposition in Bac-to-Bac 
technique, one can overcome the requirement to isolate 
plaques and the efficiency of recombination in this 
system is nearly 100%.
33,37
 Because of lengthy and 
laborious process for generating recombinant in TriEx 
expression system, we considered the expression of this 
enzyme (TG2) using Bac-to-Bac technique. To best of 
our knowledge, this is the first report of expression the 
recombinant human TG2 by Bac-to-Bac baculovirus 
expression system. 
The cDNA of human tissue transglutaminase
17
 was used 
for baculovirus Bac-to-Bac technique. Sf9 cells were 
negative for mycoplasma and their STR profiles 
confirmed no cross-contamination and misidentification 
of this cell line. The donor pFastBac HTA vector would 
add extra 6xHis-Tag sequence at N-terminal of 
recombinant protein,
19
 enabling us to use Nickel -affinity 
column chromatography for purifying recombinant 
protein. TG2 expression process was confirmed by RT-
PCR (Figure 3), SDS-PAGE (Figure 4-A) and western 
blotting (Figure 4-B). Functional analyses revealed the 
enzyme had biological activity (Figure 5 and 7). For 
directly visualizing crosslinking activity of TG2 enzyme, 
SDS-PAGE analyses were performed to reaffirm the 
functionality of the expressed enzyme (Figure 6 and 8). 
In all activity assays experiments, EDTA (100 mM or 25 
mM), as a chelating agent for calcium ions, to deactivate 
the enzymatic activity of TG2 (Figure 5,6,7 and 8). 
 
Figure 8. Fluorescence activity assay confirming by SDS-PAGE (15%) incubation 16 h. A) Gel photographed under UV light and B) the 
same gel stained by Coomassie brilliant blue. 1, transfected Sf9 cell lysate (rec TG2), 2, transfected Sf9 cell lysate (rec TG2) with 25 mM 
EDTA, 3, untransfected (Cont Neg) Sf9 cell lysate, 4, untransfected (Cont Neg) Sf9 cell lysate with 25 mM EDTA, 5, assay buffer without 
N,N dimethyl casein, 6, assay buffer without dansylcadaverine, 7, TGM2 with 25 mM EDTA, 8, TGM2 as positive control, 9, assay buffer 
as Blank, 10, protein molecular weight marker. 
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Conclusion 
TG2 was expressed efficiently by Bac-to-Bac expression 
system. Our data show that the produced recombinant 
protein (TG2) in this expression system possessed a 
considerable biological activity. The procedure of 
expression in this study is expected to be applicable for 
large-scale production of recombinant TG2 in 
baculovirus system. The further goals of this project will 
be purifying of TG2 and characterize its role in a number 
of biological networks. The expressed protein also could 
be used for diagnostic diseases, in production of antibody 
against TG2, and can be exploited searching for novel 
inhibitors of the enzyme as potential therapeutic 
approach in future. 
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